$NBIX
NEUROCRINE BIOSCIENCES INC

2024 Q4 Form 10-Q Financial Statement

#000091447524000211 Filed on October 30, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $622.1M
YoY Change 24.72%
Cost Of Revenue $8.000M
YoY Change -28.57%
Gross Profit $614.1M
YoY Change 25.94%
Gross Profit Margin 98.71%
Selling, General & Admin $234.3M
YoY Change 14.74%
% of Gross Profit 38.15%
Research & Development $195.0M
YoY Change 37.13%
% of Gross Profit 31.75%
Depreciation & Amortization $6.500M
YoY Change 18.18%
% of Gross Profit 1.06%
Operating Expenses $429.3M
YoY Change 23.93%
Operating Profit $183.8M
YoY Change 30.17%
Interest Expense $6.500M
YoY Change 490.91%
% of Operating Profit 3.54%
Other Income/Expense, Net $6.500M
YoY Change -125.39%
Pretax Income $190.3M
YoY Change 64.62%
Income Tax $60.50M
% Of Pretax Income 31.79%
Net Earnings $129.8M
YoY Change 56.2%
Net Earnings / Revenue 20.86%
Basic Earnings Per Share $1.28
Diluted Earnings Per Share $1.24
COMMON SHARES
Basic Shares Outstanding 101.2M shares 101.0M shares
Diluted Shares Outstanding 104.3M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.228B
YoY Change 12.14%
Cash & Equivalents $349.1M
Short-Term Investments $878.9M
Other Short-Term Assets $121.7M
YoY Change 12.48%
Inventory $45.80M
Prepaid Expenses
Receivables $481.1M
Other Receivables $0.00
Total Short-Term Assets $1.877B
YoY Change 13.74%
LONG-TERM ASSETS
Property, Plant & Equipment $80.00M
YoY Change 16.28%
Goodwill $6.100M
YoY Change 10.91%
Intangibles $34.50M
YoY Change -1.15%
Long-Term Investments $770.6M
YoY Change 31.17%
Other Assets $61.60M
YoY Change 42.92%
Total Long-Term Assets $1.658B
YoY Change 38.4%
TOTAL ASSETS
Total Short-Term Assets $1.877B
Total Long-Term Assets $1.658B
Total Assets $3.535B
YoY Change 24.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $277.3M
YoY Change -29.78%
Accrued Expenses $150.2M
YoY Change 19.3%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $429.7M
YoY Change -37.87%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $135.0M
YoY Change 96.79%
Total Long-Term Liabilities $135.0M
YoY Change 96.79%
TOTAL LIABILITIES
Total Short-Term Liabilities $429.7M
Total Long-Term Liabilities $135.0M
Total Liabilities $816.1M
YoY Change -3.55%
SHAREHOLDERS EQUITY
Retained Earnings $81.10M
YoY Change -126.61%
Common Stock $2.623B
YoY Change 13.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.719B
YoY Change
Total Liabilities & Shareholders Equity $3.535B
YoY Change 24.11%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income $129.8M
YoY Change 56.2%
Depreciation, Depletion And Amortization $6.500M
YoY Change 18.18%
Cash From Operating Activities $158.0M
YoY Change -25.47%
INVESTING ACTIVITIES
Capital Expenditures $8.100M
YoY Change 6.58%
Acquisitions
YoY Change
Other Investing Activities $32.80M
YoY Change -136.57%
Cash From Investing Activities $24.70M
YoY Change -125.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 26.40M
YoY Change 40.43%
NET CHANGE
Cash From Operating Activities 158.0M
Cash From Investing Activities 24.70M
Cash From Financing Activities 26.40M
Net Change In Cash 209.1M
YoY Change 56.63%
FREE CASH FLOW
Cash From Operating Activities $158.0M
Capital Expenditures $8.100M
Free Cash Flow $149.9M
YoY Change -26.66%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
101246911 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
349100000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
251100000 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
878900000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
780500000 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
481100000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
439300000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
45800000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
687500000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
257300000 usd
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
98700000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
98700000 shares
dei Entity Central Index Key
EntityCentralIndexKey
0000914475
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
NEUROCRINE BIOSCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Address Address Line1
EntityAddressAddressLine1
6027 Edgewood Bend Court
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0525145
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92130
dei City Area Code
CityAreaCode
(858)
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 us-gaap Inventory Net
InventoryNet
38300000 usd
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
121700000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
97800000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
1876600000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
1607000000 usd
CY2024Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
454400000 usd
CY2023Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
362600000 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
643900000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
276500000 usd
CY2024Q3 us-gaap Equity Securities Fv Ni Current And Noncurrent
EquitySecuritiesFvNiCurrentAndNoncurrent
126700000 usd
CY2023Q4 us-gaap Equity Securities Fv Ni Current And Noncurrent
EquitySecuritiesFvNiCurrentAndNoncurrent
161900000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
80000000.0 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
70800000 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
34500000 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
35500000 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
61600000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
49600000 usd
CY2024Q3 us-gaap Assets
Assets
3535000000 usd
CY2023Q4 us-gaap Assets
Assets
3251400000 usd
CY2024Q3 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
0 usd
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
37000000.0 usd
CY2024Q3 us-gaap Liabilities
Liabilities
816100000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
1019400000 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000.0 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000.0 shares
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
220000000.0 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
101200000 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
101200000 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
100000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
2718900000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
2232000000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1727600000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1371900000 usd
CY2024Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
8000000.0 usd
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
11200000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
24700000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
31200000 usd
CY2024Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
195000000.0 usd
CY2023Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
142200000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
545500000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
427500000 usd
CY2024Q3 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
1000000.0 usd
CY2023Q3 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
0 usd
us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
9500000 usd
us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
143900000 usd
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
234300000 usd
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
204200000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
719400000 usd
CY2024Q3 us-gaap Costs And Expenses
CostsAndExpenses
438300000 usd
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
357600000 usd
us-gaap Costs And Expenses
CostsAndExpenses
1299100000 usd
us-gaap Costs And Expenses
CostsAndExpenses
1271300000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
183800000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
428500000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
668700000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
141200000 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-600000 usd
nbix Investment Income And Other Net
InvestmentIncomeAndOtherNet
68500000 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
190300000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
60500000 usd
dei Local Phone Number
LocalPhoneNumber
617-7600
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3535000000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3251400000 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
622100000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
498800000 usd
CY2024Q3 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-16900000 usd
CY2023Q3 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-40100000 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-35200000 usd
CY2024Q3 nbix Charges Associated With Convertible Senior Notes
ChargesAssociatedWithConvertibleSeniorNotes
0 usd
CY2023Q3 nbix Charges Associated With Convertible Senior Notes
ChargesAssociatedWithConvertibleSeniorNotes
0 usd
nbix Charges Associated With Convertible Senior Notes
ChargesAssociatedWithConvertibleSeniorNotes
138400000 usd
nbix Charges Associated With Convertible Senior Notes
ChargesAssociatedWithConvertibleSeniorNotes
0 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
33300000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
115600000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
323400000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
133900000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
32500000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
85200000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
31900000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
129800000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
9100000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
800000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
5000000.0 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
5500000 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
141800000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
82500000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
245700000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
108200000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.28
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.85
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.37
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.24
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.82
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.29
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.01
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
101100000 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
97900000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
100600000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
97500000 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
104300000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
101100000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
104000000.0 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
100600000 shares
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
129800000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
12000000.0 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
41500000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
26400000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
2718900000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
1853000000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-600000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
47800000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
18800000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
2002100000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
2232000000 usd
us-gaap Net Income Loss
NetIncomeLoss
238200000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
7500000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
129100000 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
112100000 usd
nbix Charges Associated With Convertible Senior Notes
ChargesAssociatedWithConvertibleSeniorNotes
138400000 usd
us-gaap Impairment Of Leasehold
ImpairmentOfLeasehold
14000000.0 usd
us-gaap Impairment Of Leasehold
ImpairmentOfLeasehold
0 usd
us-gaap Depreciation
Depreciation
17300000 usd
us-gaap Depreciation
Depreciation
12900000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
20600000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
12000000.0 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2700000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2700000 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-35200000 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-600000 usd
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-77300000 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
3900000 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-600000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
41800000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
67900000 usd
nbix Charges Associated With Convertible Senior Notes
ChargesAssociatedWithConvertibleSeniorNotes
0 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
7500000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
147300000 usd
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
25500000 usd
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
3800000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
352900000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
266400000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
744300000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
716700000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
681600000 usd
us-gaap Payments To Acquire Equity Securities Fv Ni
PaymentsToAcquireEquitySecuritiesFvNi
31300000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
30900000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-58500000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
112100000 usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
308800000 usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29900000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
892700000 usd
us-gaap Payments To Acquire Equity Securities Fv Ni
PaymentsToAcquireEquitySecuritiesFvNi
0 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
22900000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-265300000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-196700000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
259100000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
270700000 usd
CY2024Q3 nbix Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
100000 usd
CY2024Q3 nbix Debt Securities Available For Sale Fair Value Current
DebtSecuritiesAvailableForSaleFairValueCurrent
878900000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
781700000 usd
CY2023Q4 nbix Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
300000 usd
CY2023Q4 nbix Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
1500000 usd
CY2023Q4 nbix Debt Securities Available For Sale Fair Value Current
DebtSecuritiesAvailableForSaleFairValueCurrent
780500000 usd
CY2024Q3 nbix Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Noncurrent
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
7000000.0 usd
CY2024Q3 nbix Debt Securities Available For Sale Fair Value Noncurrent
DebtSecuritiesAvailableForSaleFairValueNoncurrent
643900000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Amortized Cost Noncurrent
DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
684600000 usd
CY2023Q4 nbix Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Noncurrent
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
3400000 usd
CY2023Q4 nbix Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Noncurrent
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
500000 usd
CY2023Q4 nbix Debt Securities Available For Sale Fair Value Noncurrent
DebtSecuritiesAvailableForSaleFairValueNoncurrent
687500000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
13500000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
11200000 usd
CY2024Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
NBIX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
392700000 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
448800000 usd
CY2023Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
170100000 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
35900000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
429700000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
654800000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
251400000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
258300000 usd
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
135000000.0 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
106300000 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
220000000.0 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
100000 usd
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2623200000 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2382000000 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
14500000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
7000000.0 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
81100000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-157100000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
100600000 usd
CY2024Q3 nbix Investment Income And Other Net
InvestmentIncomeAndOtherNet
23400000 usd
CY2023Q3 nbix Investment Income And Other Net
InvestmentIncomeAndOtherNet
14500000 usd
nbix Investment Income And Other Net
InvestmentIncomeAndOtherNet
33900000 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6500000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-25600000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-105100000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
83100000 usd
us-gaap Net Income Loss
NetIncomeLoss
238200000 usd
us-gaap Net Income Loss
NetIncomeLoss
102000000.0 usd
CY2024Q3 us-gaap Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
-2900000 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
1400000 usd
us-gaap Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
-2500000 usd
us-gaap Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
-700000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.05
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
2509200000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
83100000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
2718900000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1707800000 usd
us-gaap Net Income Loss
NetIncomeLoss
102000000.0 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
6200000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
156200000 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
29900000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
2002100000 usd
us-gaap Net Income Loss
NetIncomeLoss
238200000 usd
us-gaap Net Income Loss
NetIncomeLoss
102000000.0 usd
us-gaap Share Based Compensation
ShareBasedCompensation
129100000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
156200000 usd
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-91800000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-6300000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-38700000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
29900000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
300000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
98000000.0 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
31000000.0 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
357100000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
301700000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
800000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
900000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
9000000.0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1800000 usd
us-gaap Interest Paid Net
InterestPaidNet
1600000 usd
us-gaap Interest Paid Net
InterestPaidNet
1900000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
144500000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
5000000.0 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
877400000 usd
CY2024Q3 nbix Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
1600000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Amortized Cost Noncurrent
DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
637100000 usd
CY2024Q3 nbix Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Noncurrent
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
200000 usd
us-gaap Debt Securities Available For Sale Accrued Interest Writeoff
DebtSecuritiesAvailableForSaleAccruedInterestWriteoff
0 usd
us-gaap Debt Securities Available For Sale Accrued Interest Writeoff
DebtSecuritiesAvailableForSaleAccruedInterestWriteoff
0 usd
CY2024Q3 us-gaap Investments
Investments
1998600000 usd
CY2023Q4 us-gaap Investments
Investments
1881000000 usd
CY2024Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
23700000 usd
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
21500000 usd
CY2024Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
10600000 usd
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
9700000 usd
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
11500000 usd
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
12300000 usd
CY2024Q3 us-gaap Inventory Gross
InventoryGross
45800000 usd
CY2023Q4 us-gaap Inventory Gross
InventoryGross
43500000 usd
CY2024Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
0 usd
CY2023Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
5200000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
45800000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
38300000 usd
CY2024Q3 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
138900000 usd
CY2023Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
139300000 usd
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
77100000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
86200000 usd
CY2024Q3 nbix Accrued Branded Prescription Drug Fee
AccruedBrandedPrescriptionDrugFee
42700000 usd
CY2023Q4 nbix Accrued Branded Prescription Drug Fee
AccruedBrandedPrescriptionDrugFee
45700000 usd
CY2024Q3 nbix Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
38300000 usd
CY2023Q4 nbix Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
44300000 usd
CY2024Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
95700000 usd
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
133300000 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
392700000 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
448800000 usd
CY2024Q3 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
134900000 usd
CY2023Q4 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
96000000.0 usd
CY2024Q3 nbix Prescription Drug Fee Noncurrent
PrescriptionDrugFeeNoncurrent
100000 usd
CY2023Q4 nbix Prescription Drug Fee Noncurrent
PrescriptionDrugFeeNoncurrent
10300000 usd
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
135000000.0 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
106300000 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
349100000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
293700000 usd
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
8000000.0 usd
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
8000000.0 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
357100000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
301700000 usd
CY2023Q4 us-gaap Goodwill
Goodwill
5800000 usd
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
300000 usd
CY2024Q3 us-gaap Goodwill
Goodwill
6100000 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
34500000 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
35500000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
900000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
3800000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
3800000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
3800000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
3800000 usd
CY2024Q3 nbix Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
14500000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
27900000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
12300000 usd
us-gaap Sublease Income
SubleaseIncome
1300000 usd
us-gaap Sublease Income
SubleaseIncome
300000 usd
nbix Operating Leases Rent Expense Net Sublease Income
OperatingLeasesRentExpenseNetSubleaseIncome
26600000 usd
nbix Operating Leases Rent Expense Net Sublease Income
OperatingLeasesRentExpenseNetSubleaseIncome
12000000.0 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
24000000.0 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
13400000 usd
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y3M18D
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y2M12D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.050
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.054
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
9000000.0 usd
CY2024Q3 us-gaap Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year
LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
800000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
35400000 usd
CY2024Q3 us-gaap Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
3500000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
34900000 usd
CY2024Q3 us-gaap Lessor Operating Lease Payments To Be Received Two Years
LessorOperatingLeasePaymentsToBeReceivedTwoYears
3500000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
35800000 usd
CY2024Q3 us-gaap Lessor Operating Lease Payments To Be Received Three Years
LessorOperatingLeasePaymentsToBeReceivedThreeYears
3500000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
36600000 usd
CY2024Q3 us-gaap Lessor Operating Lease Payments To Be Received Four Years
LessorOperatingLeasePaymentsToBeReceivedFourYears
3500000 usd
CY2024Q3 nbix Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
220400000 usd
CY2024Q3 nbix Lessor Operating Lease Payment To Be Received After Year Four
LessorOperatingLeasePaymentToBeReceivedAfterYearFour
8800000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
372100000 usd
CY2024Q3 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
23600000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
85900000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
286200000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
34800000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
251400000 usd
CY2024Q3 us-gaap Unrecorded Unconditional Purchase Obligation Balance On First Anniversary
UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary
5600000 usd
CY2024Q3 us-gaap Unrecorded Unconditional Purchase Obligation Balance On Second Anniversary
UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary
22600000 usd
CY2024Q3 us-gaap Unrecorded Unconditional Purchase Obligation Balance On Third Anniversary
UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary
23300000 usd
CY2024Q3 us-gaap Unrecorded Unconditional Purchase Obligation Balance On Fourth Anniversary
UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary
24000000.0 usd
CY2024Q3 nbix Unrecorded Unconditional Purchase Obligation To Be Paid After Year Four
UnrecordedUnconditionalPurchaseObligationToBePaidAfterYearFour
214400000 usd
CY2024Q2 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
14000000.0 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
126600000 usd
us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
-9600000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2200000 usd
nbix Charges Associated With Convertible Senior Notes
ChargesAssociatedWithConvertibleSeniorNotes
138400000 usd
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
129800000 usd
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
129800000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
83100000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
83100000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
238200000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
238200000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
102000000.0 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
102000000.0 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
101100000 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
97900000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
100600000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
97500000 shares
CY2024Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
3200000 shares
CY2023Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
3200000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
3400000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
3100000 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
104300000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
101100000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
104000000.0 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
100600000 shares
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.28
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.85
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.37
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.05
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.24
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.82
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.29
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.01
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1700000 shares
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4400000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1900000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5200000 shares
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false

Files In Submission

Name View Source Status
0000914475-24-000211-index-headers.html Edgar Link pending
0000914475-24-000211-index.html Edgar Link pending
0000914475-24-000211.txt Edgar Link pending
0000914475-24-000211-xbrl.zip Edgar Link pending
exhibit101-2011equityinc.htm Edgar Link pending
exhibit101-2011equityinc001.jpg Edgar Link pending
exhibit101-2011equityinc002.jpg Edgar Link pending
exhibit101-2011equityinc003.jpg Edgar Link pending
exhibit101-2011equityinc004.jpg Edgar Link pending
exhibit101-2011equityinc005.jpg Edgar Link pending
exhibit101-2011equityinc006.jpg Edgar Link pending
exhibit101-2011equityinc007.jpg Edgar Link pending
exhibit101-2011equityinc008.jpg Edgar Link pending
exhibit102-2020equityinc.htm Edgar Link pending
exhibit102-2020equityinc001.jpg Edgar Link pending
exhibit102-2020equityinc002.jpg Edgar Link pending
exhibit102-2020equityinc003.jpg Edgar Link pending
exhibit102-2020equityinc004.jpg Edgar Link pending
exhibit102-2020equityinc005.jpg Edgar Link pending
exhibit102-2020equityinc006.jpg Edgar Link pending
exhibit102-2020equityinc007.jpg Edgar Link pending
exhibit102-2020equityinc008.jpg Edgar Link pending
exhibit102-2020equityinc009.jpg Edgar Link pending
exhibit103-formofoptiong.htm Edgar Link pending
exhibit103-formofoptiong001.jpg Edgar Link pending
exhibit103-formofoptiong002.jpg Edgar Link pending
exhibit32-bylawsasamende.htm Edgar Link pending
exhibit32-bylawsasamende001.jpg Edgar Link pending
exhibit32-bylawsasamende002.jpg Edgar Link pending
exhibit32-bylawsasamende003.jpg Edgar Link pending
exhibit32-bylawsasamende004.jpg Edgar Link pending
exhibit32-bylawsasamende005.jpg Edgar Link pending
exhibit32-bylawsasamende006.jpg Edgar Link pending
exhibit32-bylawsasamende007.jpg Edgar Link pending
exhibit32-bylawsasamende008.jpg Edgar Link pending
exhibit32-bylawsasamende009.jpg Edgar Link pending
exhibit32-bylawsasamende010.jpg Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nbix-20240930.htm Edgar Link pending
nbix-20240930.xsd Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
nbix-20240930_g1.jpg Edgar Link pending
q3-2024xexhibit311.htm Edgar Link pending
q3-2024xexhibit312.htm Edgar Link pending
q3-2024xexhibit32.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
nbix-20240930_lab.xml Edgar Link unprocessable
nbix-20240930_pre.xml Edgar Link unprocessable
nbix-20240930_htm.xml Edgar Link completed
nbix-20240930_cal.xml Edgar Link unprocessable
nbix-20240930_def.xml Edgar Link unprocessable